BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7859936)

  • 1. Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM.
    Shank ML; Del Prato S; DeFronzo RA
    Diabetes; 1995 Feb; 44(2):165-72. PubMed ID: 7859936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
    Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
    Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
    Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
    Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
    Goldstein BJ; Pans M; Rubin CJ
    Clin Ther; 2003 Mar; 25(3):890-903. PubMed ID: 12852706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC; Tsang LW; Sorensen JP; Cockram CS
    Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of glipizide GITS and glibenclamide on metabolic control, hepatic glucose production, and insulin secretion in patients with type 2 diabetes.
    Go EH; Kyriakidou-Himonas M; Berelowitz M
    Diabetes Metab Res Rev; 2004; 20(3):225-31. PubMed ID: 15133754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from low-dose insulin therapy to glipizide in patients with non-insulin-dependent diabetes mellitus.
    Rosenstock J; Meisel A; Raskin P
    Am J Med; 1987 Sep; 83(3A):10-5. PubMed ID: 3307402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM.
    Cusi K; Cunningham GR; Comstock JP
    Diabetes Care; 1995 Jun; 18(6):843-51. PubMed ID: 7555511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.
    Riddle MC; Schneider J
    Diabetes Care; 1998 Jul; 21(7):1052-7. PubMed ID: 9653594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM.
    Berelowitz M; Fischette C; Cefalu W; Schade DS; Sutfin T; Kourides IA
    Diabetes Care; 1994 Dec; 17(12):1460-4. PubMed ID: 7882817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of short-term insulin therapy upon therapeutic response to glipizide.
    Schwartz SL; Fischer JS; Kipnes MS; Boyle M
    Am J Med; 1987 Sep; 83(3A):22-30. PubMed ID: 3307403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients.
    Simpson HC; Sturley R; Stirling CA; Reckless JP
    Diabet Med; 1990 Feb; 7(2):143-7. PubMed ID: 2137755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.
    Cusi K; Consoli A; DeFronzo RA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4059-67. PubMed ID: 8923861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin versus glipizide treatment in patients with non-insulin-dependent diabetes mellitus. Effects on blood pressure and glucose tolerance.
    Levy J; Vandenberg M; Grunberger G
    Am J Hypertens; 1995 May; 8(5 Pt 1):445-53. PubMed ID: 7662219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
    Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
    JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus.
    Feinglos MN; Thacker CR; Lobaugh B; DeAtkine DD; McNeill DB; English JS; Bursey DL
    Diabetes Res Clin Pract; 1998 Mar; 39(3):193-9. PubMed ID: 9649951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.